SLC5A2 and Cognitive impairment: Another study [20] further supported this hypothesis, demonstrating the benefit of SGLT2 inhibitors in the progression of mild cognitive impairment (MCI) and a statistically significant improvement in the Mini-Mental State Examination (MMSE).